Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of oral NTRA-2112 in preterm infants with intestinal malabsorption
MOH_2017-05-29_000468Phase 3Completed
- Sponsor
- PharmAlgan
- Start
- Dec 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elgn-gi in intestinal malabsorption (3 arms), sponsored by PharmAlgan. Primary endpoint: Time to full enteral feeding. Started Dec 2016; status: completed.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on MOH_2017-05-29_000468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-05-29_000468.